Abbott, Enanta Pharma Advance Hepatitis C Collaboration
The trial is expected to evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration and polymerase inhibitors ABT-333 and ABT-072 currently
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.